Core Viewpoint - Quantum BioPharma Ltd. has engaged Enterprise Canada Inc. and Empire Market Ventures, LLC to enhance its public relations and investor awareness efforts across key markets [1][2][6] Group 1: Engagement of Agencies - The decision to retain the services of Enterprise and Empire was made after a thorough review of available capital [2] - Enterprise has been engaged for an indefinite period starting December 18, 2024, with a structured payment plan totaling C$10,000 for Phase 1 and a monthly retainer of C$5,000 thereafter [3][4] - Empire has been contracted for three months starting February 7, 2025, with a total fee of US$25,000 [5][6] Group 2: Services Provided - Enterprise will assist with public relations strategy, including narrative development, key messaging, and media relationships [4] - Empire will provide investor awareness services, including access to exclusive mailing lists and content creation aimed at increasing investor engagement [6] Group 3: Product Updates - Quantum BioPharma's product unbuzzd™ is a rapid alcohol detoxification beverage, with a ready-to-drink formulation expected to be available in Q1 2025 [7][9] - rekvry™ is designed for alcohol misuse treatment, targeting emergency and hospital settings to reduce healthcare costs [7][9] - LUCID-21-302 is a new chemical entity aimed at treating demyelinating diseases, with an initial focus on multiple sclerosis [8][9] Group 4: Company Overview - Quantum BioPharma is focused on developing innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse [10] - The company retains a 25.71% ownership stake in Celly Nutrition, which markets unbuzzd™, and is entitled to a 7% royalty on sales until reaching $250 million [11]

Core Viewpoint - Quantum BioPharma Ltd. announced that its licensee, Celly Nutrition Corporation, is raising up to $10 million USD and exploring an initial public offering on a major US exchange, which indicates strong market interest in their product unbuzzd, a beverage designed to enhance alcohol metabolism and reduce hangover symptoms [1][3][4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse [5]. - The company retains a 25.71% ownership stake in Celly Nutrition as of June 30, 2024, and has a royalty agreement that includes 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty rate drops to 3% indefinitely [2][5]. Product Details - unbuzzd is a scientifically-backed beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms, appealing to consumers who wish to enjoy alcohol responsibly [7][8]. - Clinical trials demonstrated that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster than a placebo within 30 minutes, improves alertness, stabilizes heart rate and blood pressure, and significantly reduces hangover symptoms [14]. Strategic Developments - Celly Nutrition has engaged a leading New York investment bank to assist with financial advisory services and to manage a proposed public offering, indicating a strategic move towards expanding its market presence [3][6]. - The CEO of Celly Nutrition emphasized the importance of this capital raise for accelerating marketing and sales development of unbuzzd, reflecting the company's growth strategy [3].

TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolis ...

TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased USD $1,000,000 Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. As well, going forward the Company will allow for future financing and other transactions to be carried out in cryptocurrency. This move reflects the company's belief in t ...